Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant

Human Gene Therapy

Volumn 7, Issue 4, 1996, Pages 525-529

  Cayeux, Sophie ^a   Beck, Christian ^b   Dörken, Bernd ^b   Blankenstein, Thomas ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOLOGY; CELL VIABILITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PROPIONIBACTERIUM ACNES; RETROVIRUS; TUMOR REJECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD80; FEMALE; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROPIONIBACTERIUM ACNES; TRANSFECTION; TUMOR CELLS, CULTURED; VACCINES; VACCINES, SYNTHETIC;

ANIMALIA; CORYNEBACTERIUM PARVUM; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0029914307     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.4-525     Document Type: Article

References (17)

1. ALLIONE, A., CONSALVO, M., NANNI, P., LOLLINI, P.L., CAVALLO, F., GIOVARELLI, M., FORNI, M., GULINO, A., COLOMBO, M.P. DELLABONA, P., HOCK, H., BLANKENSTEIN, T. ROSENTHAL, F.M, GANSBACHER, B., BOSCO, M.C., MUSSO, T., GUSELLA, L., and FORNI, G. (1994). Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor a, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res. 54, 6022-6026.
2. BLANKENSTEIN, T. (1994). Increasing tumour immunogenicity by genetic modification. Eur. J. Cancer. 30A, 1182-1187.
3. CAYEUX, S., BECK, C., AICHER, A., DÖRKEN, B., and BLANKENSTEIN, T. (1995). Tumor cells cotransfected with interleukin 7 and B7.1 genes induce CD25 and CD28 on tumor infiltrating lymphocytes and are strong vaccines. Eur. J. Immunol. 25, 2325-2331.
4. CHEN, L., McGOWAN, P., ASHE, S., JOHNSTON, Y., LI, Y., HELLSTRÖM, I., and HELLSTRÖM, K.E. (1994). Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179, 523-532.
5. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543.
6. ERARD, F., WILD, M.T., GARCIA-SANZ, J.A., and LE GROS, G. (1993). Switch of CD8 T cells to noncytolytic CD8-CD4- cells that make TH2 cytokines and help B cells. Science 260, 1802-1805.
7. HOCK, H., DORSCH, M., KUNZENDORF, U., QIN, Z., DIAMANTSTEIN, T., and BLANKENSTEIN, T. (1993a). Mechanisms of rejection induced by tumor cell targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor or interferon-γ. Proc. Natl. Acad. Sci. USA, 90, 2774-2778.
8. HOCK, H., DORSCH, M., KUNZENDORF, U., UBERLA, K., QIN, Z., DIAMANTSTEIN, T., and BLANKENSTEIN, T. (1993b). Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res. 53, 714-716.
9. LI, W., DIAMANTSTEIN, T., and BLANKENSTEIN, T. (1990). Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. Mol. Immunol. 27, 1331-1337.
10. LUPTON, S.D., BRUNTON, L.L., KALBERG, V.A., and OVERELL, R.W. (1991). Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol. Cell. Biol. 11, 3374-3378.
11. McARTHUR, J.G., and RAULET, D.H. (1993). CD28-induced costimulation of T helper type 2 cells mediated by induction of responsiveness to interleukin 4. J. Exp. Med. 178, 1645-1653.
12. OETTGEN, H.F., and OLD, L.J. (1991). The history of cancer immunotherapy. In The Biologic Therapy of Cancer. V.T. De Vita, S. Hellman, and S.A. Rosenberg, eds. (J.B. Lippincott Co., Philadelphia) pp. 87-119.
13. PERICLE, F., GIOVARELLI, M., COLOMBO, M.P., FERRARI, G., MUSIANI, P., MODESTI, A., CAVALLO, F., DI PIERRO, F., NOVELLI, F., and FORNI, G. (1994). An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J. Immunol. 153, 5659-5673.
14. RAMARATHINAM, L., CASTLE, M., WU, Y., and LIU, Y. (1994). T cell costimulation by B7/BB1 induces CD8 T cell-dependent Tumor rejection: An important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179, 1205-1214.
15. SCHENDEL, D.J., GANSBACHER, B., OBERNEDER, R., KRIEGMAIR, M., HOFSTETTER, A., RIETHMÜLLER, G., and SEGURADO, O.G. (1993). Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2 restricted lysis of autologous and allogeneic tumor lines. J. Immunol. 151, 4209-4220.
16. TEPPER, R.I., PATTENDALE, P.K., and LEDER, P. (1989). Murine interleukin 4 displays potent anti-tumor activity in vivo. Cell 57, 503-512.
17. TEPPER, R.I., COFFMAN, R.L., and LEDER, P. (1992). An eosinophil-dependent mechanism for the anti-tumor effect of interleukin 4. Science 257, 548-551.